*wjpmr, 2024, 10(9), 270-279*

**SJIF Impact Factor: 6.842**

**WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH**

www.wjpmr.com

**Review Article**

**ISSN 2455-3301**

**WJPMR**

# THE ROLE OF ARTIFICIAL INTELLIGENCE IN PARKINSON'S DISEASE: A COMPREHENSIVE REVIEW

**Moh Aijaz[1], Ramesh Kumar A.[2], Shmmon Ahmad[3], Md Shams Raja[4], Rajneesh Kumar Gupta[5] and Rajarshi Yadav[5]***

[1]School of Pharmacy, Graphic Era Hill University, Dehradun, Uttarakhand, India.
[2]Department of Mechatronics Engineering, K.S. Rangasamy College of Technology,Tiruchengode, Tamil Nadu, India.
[3]Glocal School of Pharmacy. Glocal University, Mirzapur Pole, Saharanpur, Uttar Pradesh, India.
[4]Seth Vishambhar Nath Institute of Pharmacy, Lucknow, India.
[5]Department of Pharmaceutical Science and Technology, Madan Mohan Malaviya University of Technology, Gorakhpur, Uttar Pradesh, India.

***Corresponding Author: Rajarshi Yadav**

Department of Pharmaceutical Science and Technology, Madan Mohan Malaviya University of Technology, Gorakhpur, Uttar Pradesh, India. **Email ID:** rajarshiyadav100@gmail.com

**Article Received on 21/07/2024** **Article Revised on 11/08/2024** **Article Accepted on 01/09/2024**

## ABSTRACT

Parkinson's Disease (PD) impacts millions worldwide with both motor and non-motor symptoms. Traditional diagnostic methods often miss early signs, delaying treatment. However, recent developments in Artificial Intelligence (AI) offer new hope. AI can now aid in early detection, continuous monitoring, and tailored treatment of PD. Techniques like machine learning and deep learning can be examined through complex data to find early PD signs, enhancing diagnostic accuracy. AI-driven imaging can recognize subtle brain changes tied to PD, and wearable tech provides real-time updates on symptoms and disease progression. Predictive analytics help adjust treatments as needed, whereas AI-based plans improve effectiveness and reduce side effects. AI also accelerates drug discovery and finds new uses for existing drugs. Besides clinical benefits, AI tools like virtual assistants and chatbots improve patient engagement and self-care, and remote monitoring makes healthcare more accessible. AI also helps caregivers with practical insights and recommendations. Despite these advances, challenges such as data privacy, biases in algorithms, and transparency issues remain. Ensuring AI tools are accessible and affordable is crucial to prevent deteriorating health disparities. This review looks at how AI is shaping PD management, considering its technological, ethical, and social impacts to better patient outcomes.

**KEYWORDS:** Parkinson's Disease, Artificial Intelligence, Early Diagnosis, Disease Monitoring, Personalized Treatment, Deep Brain Stimulation, Drug Discovery, Remote Patient Monitoring.

## 1. INTRODUCTION

Parkinson's Disease (PD) is a complex neurodegenerative disorder primarily known for its motor symptoms, which include tremors, rigidity, and bradykinesia. These motor symptoms are the most recognizable and often the earliest signs of the disease, leading to difficulties in movement and coordination.[1] Tremors, or rhythmic shaking, usually begin in the hands and can spread to other parts of the body. Rigidity refers to stiffness in the muscles, which can make movements slow and painful. Bradykinesia, or slowness of movement, is another hallmark symptom that severely affects a person's ability to perform everyday tasks. However, PD is not solely characterized by motor symptoms. Non-motor symptoms also play a significant role in the disease's progression and impact on patients' lives.[2] Cognitive impairment is common, ranging from mild cognitive decline to severe dementia. Mood disorders, such as depression and anxiety, are frequently observed and can exacerbate the challenges faced by individuals with PD. Sleep disturbances, including insomnia and rapid eye movement (REM) sleep behavior disorder, further complicate the management of the disease. These non-motor symptoms can appear years before the motor symptoms, highlighting the need for early diagnosis and intervention.[3]

The progressive nature of PD makes early diagnosis crucial. Identifying the disease at an early stage allows for more effective management of symptoms and can significantly improve the quality of life for patients. Traditional diagnostic methods rely heavily on clinical assessments and imaging techniques, such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. While these methods are useful, they often fail to detect PD in its early stages.[4]

Clinical assessments depend on the observation of motor symptoms, which may not be evident until significant neuronal damage has occurred. Imaging techniques, though advanced, are not always sensitive enough to detect the subtle changes in the brain associated with early PD.[5]

Artificial Intelligence (AI) has emerged as a transformative technology with the potential to revolutionize the diagnosis and management of PD. AI encompasses a range of techniques, including machine learning (ML), deep learning, natural language processing (NLP), and computer vision. These technologies enable computers to learn from data, recognize patterns, and make predictions with a level of accuracy that often surpasses human capabilities.[6]

In the context of PD, AI offers several promising applications. For early diagnosis, AI can analyze large datasets of clinical records, imaging scans, and even genetic information to identify patterns that may indicate the presence of PD before traditional methods can. Machine learning algorithms can be trained to recognize subtle changes in motor function and cognitive abilities, providing a more comprehensive and early diagnosis. Monitoring disease progression is another area where AI can make a significant impact.[7] Wearable devices and sensors can collect continuous data on a patient's movements, sleep patterns, and other vital signs. AI algorithms can analyze this data in real-time to track the progression of the disease and adjust treatment plans accordingly. This personalized approach ensures that patients receive the most effective treatments based on their unique condition.[8]

AI also plays a crucial role in personalizing treatment plans. By analyzing data from numerous patients, AI can identify which treatments are most effective for specific subsets of patients. This data-driven approach enables healthcare providers to tailor treatments to individual patients, improving outcomes and reducing side effects.[9]




**Fig. 1: Illustration of Parkinson' Disease.**

Thus, AI can support patient management by providing tools for remote monitoring and telemedicine. Patients can use mobile apps to report symptoms, receive reminders for medication, and access educational resources. AI-powered chatbots and virtual assistants can offer support and guidance, making it easier for patients to manage their condition on a daily basis.[10] Despite the significant potential of AI in Parkinson's Disease (PD), there are important ethical considerations to address, including privacy concerns related to the handling of sensitive patient data, the need for transparent and explainable AI algorithms, and ensuring equitable access to AI technologies.[11] This review aims to provide a comprehensive exploration of the role of AI in PD, covering technological advancements, ethical considerations, and future directions. By harnessing the power of AI, we can improve the early diagnosis, monitoring, and management of Parkinson's Disease, ultimately enhancing the quality of life for those affected by this challenging condition.

## 2. AI in early diagnosis

**Importance of Early Diagnosis in PD**

Early diagnosis of PD is critical for implementing timely interventions that can slow disease progression and manage symptoms more effectively. Current diagnostic methods often involve clinical evaluation and neuroimaging, which may not identify PD until motor symptoms become apparent. As a result, there is a pressing need for more sensitive and specific diagnostic tools.[12]

The delay in diagnosis can result in missed opportunities for early therapeutic interventions, which are believed to be more effective in the initial stages of the disease. Furthermore, early diagnosis can help in better understanding the disease mechanisms and in designing clinical trials for new treatments, as it allows for the recruitment of patients in the earlier stages of PD.[13]




**AI Techniques Used for Early Detection**

**Machine learning algorithms**

Machine learning (ML) algorithms have demonstrated considerable potential in identifying patterns indicative of Parkinson's Disease (PD) from complex datasets. Supervised learning techniques, such as support vector machines (SVM), random forests, and logistic regression, have been employed to classify PD patients based on various biomarkers, including genetic data, biochemical markers, and clinical features.[14] For example, researchers have developed ML models that analyze olfactory function, as loss of smell is an early symptom of PD. By combining olfactory data with other clinical features, these models can distinguish PD patients from healthy controls with high accuracy.[15] Another approach involves analyzing gait and movement patterns using wearable sensors. Machine learning algorithms can process this data to identify subtle changes in motor function that precede the onset of more noticeable symptoms.[16] Several studies have shown the efficacy of ML algorithms in early diagnosis; for instance, an algorithm using a combination of clinical data and wearable sensor data was able to classify early PD patients with an accuracy of over 90%. This demonstrates the potential of ML in improving the diagnostic process and aiding clinicians in identifying PD at its earliest stages.[17]

**Image analysis**

AI-powered image analysis is revolutionizing the field of medical imaging. Convolutional Neural Networks (CNNs), a type of deep learning algorithm, have shown promise in analyzing brain imaging data to detect PD-related abnormalities.[17] MRI and PET scans provide detailed images of brain structures and metabolic activity, which AI models can interpret to identify characteristic changes associated with PD. For example, a study using CNNs to analyze dopamine transporter (DAT) imaging demonstrated that AI could accurately distinguish PD patients from healthy individuals.[18] These models can detect reductions in dopamine levels, a hallmark of PD, even in the early stages of the disease. By automating the analysis of imaging data, AI reduces the burden on radiologists and enhances the precision of PD diagnosis.[19]

Othe than this, AI algorithms can be trained to recognize specific patterns associated with PD, such as the loss of dopaminergic neurons in the substantia nigra. These patterns are often difficult to detect with the naked eye but can be identified with high accuracy using AI, leading to earlier and more accurate diagnoses.[20]

**Voice and Handwriting Analysis**

Changes in voice and handwriting are early indicators of PD, often preceding motor symptoms. AI models leveraging natural language processing (NLP) and pattern recognition techniques can analyze voice recordings and handwriting samples to detect PD with high accuracy.[21] Speech analysis focuses on features such as pitch, tone, and articulation, while handwriting analysis examines aspects like tremor frequency, writing speed, and letter formation. Research has shown that AI can identify PD-related changes in voice and handwriting with sensitivity and specificity comparable to traditional diagnostic methods.[22] For example, an AI model analyzing voice recordings may detect subtle changes in speech patterns that indicate early PD, allowing for timely intervention and management.[23]

Studies have demonstrated the potential of these techniques in clinical settings. For instance, one study found that an AI-based handwriting analysis system could distinguish between PD patients and healthy controls with an accuracy of 85%. Similarly, AI-based voice analysis has been shown to accurately detect PD with over 80% accuracy, making it a valuable tool for early diagnosis.[24]

## 3. AI in monitoring disease progression

### Continuous monitoring vs. periodic check-ups

Traditional approaches to monitoring PD involve periodic clinical assessments, which may not capture the dynamic nature of disease progression. Continuous monitoring offers a more comprehensive view of symptom fluctuations and disease trajectory.[25] AI enables the integration of continuous data collection with advanced analytics, providing real-time insights into patient conditions. Continuous monitoring can provide a wealth of data that captures the day-to-day variations in symptoms experienced by PD patients.[26] This data can be invaluable in understanding disease progression and in adjusting treatment plans to better manage symptoms. Moreover, continuous monitoring can help in identifying patterns and triggers of symptom exacerbation, leading to more effective management strategies.[27]

### Wearable Devices and Sensors

Wearable devices equipped with sensors play a crucial role in continuous monitoring of PD symptoms. These devices can track motor symptoms such as tremors, gait disturbances, and bradykinesia, as well as non-motor symptoms like sleep patterns and heart rate variability.[28] AI algorithms process the data collected from wearables to quantify symptom severity, identify patterns, and detect changes over time.[29] For instance, a study utilizing wearable sensors to monitor tremors in PD patients demonstrated that AI could accurately assess tremor severity and frequency. This information allows healthcare providers to adjust treatment plans based on real-time data, improving symptom management and patient outcomes. Wearable devices such as smartwatches and fitness trackers can collect continuous data on various parameters, including movement, heart rate, and sleep patterns.[30] AI algorithms can analyze this data to provide insights into the patient's condition and to detect early signs of disease progression. This real-time data can be used to adjust treatment plans and to provide timely interventions, improving patient outcomes and quality of life.[31]

### Data Collection and Analysis

The integration of AI with big data analytics enables the processing of large datasets collected from wearable devices, mobile health applications, and electronic health records (EHRs). AI models can analyze this data to identify patterns and trends in disease progression, predict exacerbations, and optimize treatment strategies.[32]

Researchers have developed AI models that combine data from multiple sources, such as wearable sensors, smartphone apps, and clinical records, to create comprehensive profiles of PD patients. These models can predict disease progression, identify risk factors for complications, and provide personalized recommendations for managing symptoms. Big data analytics can also help in identifying correlations and trends that may not be apparent from smaller datasets.[33] By analyzing large volumes of data, AI can identify early signs of disease progression and potential triggers of symptom exacerbation, allowing for more proactive management of PD.[34]

### Predictive analytics for disease progression

AI models can leverage historical data and real-time monitoring to predict disease progression in PD patients. Predictive analytics can identify early signs of deterioration, allowing for proactive intervention and treatment adjustments.[35] Machine learning algorithms, such as recurrent neural networks (RNNs) and long short-term memory (LSTM) networks, are particularly suited for time-series analysis and prediction.[36]

An AI model analyzing longitudinal data from PD patients might predict the onset of freezing of gait (FoG), a common and debilitating symptom. By identifying patients at risk of developing FoG, healthcare providers can implement targeted interventions to prevent or mitigate its impact.[37] Predictive analytics can also help in identifying patients who are likely to respond to specific treatments or who may require more intensive monitoring. By analyzing historical data and identifying patterns, AI can provide personalized recommendations for managing PD, improving patient outcomes and quality of life.[38]

## 4. AI in personalized treatment

### Customized Treatment Plans

Personalized treatment is essential for optimizing outcomes in PD patients, as the disease manifests differently in each individual. AI can analyze patient-specific data, including genetic, biochemical, and clinical information, to create customized treatment plans. Machine learning models can predict individual responses to different therapies, enabling tailored interventions. For instance, AI models can analyze genetic data to identify patients who may respond better to certain medications or therapies.[39] By considering factors such as age, disease stage, and comorbidities, AI can recommend personalized treatment plans that maximize efficacy and minimize side effects.[40] Personalized treatment plans can also take into account patient preferences and lifestyle factors, ensuring that the treatment is tailored to the individual's needs and circumstances. This approach can improve adherence to treatment plans and enhance patient satisfaction and quality of life.[41]

**AI in Drug Discovery and Repurposing**

AI accelerates the drug discovery process by analyzing biological data to identify potential therapeutic targets. Machine learning algorithms can screen large datasets of chemical compounds to predict their efficacy and safety in treating PD.[42] Additionally, AI can repurpose existing drugs for PD treatment by finding new applications for known compounds.[43]

For instance, researchers have used AI to identify compounds that can inhibit alpha-synuclein aggregation, a key pathological feature of PD. By screening thousands of compounds, AI models can rapidly identify promising candidates for further testing, speeding up the drug discovery process.[44] Drug repurposing involves identifying new uses for existing drugs, which can significantly reduce the time and cost involved in bringing new treatments to market. AI can analyze large datasets of clinical and molecular data to identify potential repurposing opportunities, providing new treatment options for PD patients.[45]

**Optimization of Deep Brain Stimulation (DBS) Parameters**

Deep Brain Stimulation (DBS) is an established treatment for PD, involving the implantation of electrodes in specific brain regions to modulate neural activity. The efficacy of DBS depends on precise parameter settings, which are traditionally adjusted through trial and error. AI can optimize DBS parameters by continuously monitoring patient responses and adjusting stimulation settings in real-time.[46] For instance, AI models can analyze data from implanted devices to identify optimal stimulation parameters for each patient. This approach reduces the time and effort required to fine-tune DBS settings, enhancing treatment efficacy and patient outcomes.[47]

By continuously monitoring patient responses to DBS and adjusting stimulation parameters in real-time, AI can ensure that patients receive the most effective treatment possible.[48] This approach can also help in identifying patients who may benefit from DBS and in optimizing the timing and intensity of stimulation, improving patient outcomes and quality of life.[49]

## 5. AI in Patient Management and Support

**AI-powered Virtual Assistants and Chatbots**

Virtual assistants and chatbots powered by AI can provide patients with information, reminders, and emotional support, enhancing patient engagement and self-management. These tools can answer common questions, offer reminders, and provide coping strategies for managing symptoms.[50] For example, an AI-powered chatbot designed for PD patients can provide real-time advice on managing symptoms, suggest exercises to improve mobility, and offer emotional support. By interacting with patients regularly, virtual assistants can help monitor symptoms and encourage adherence to treatment plans.[51] Virtual assistants can also provide personalized recommendations based on the patient's condition and preferences, helping patients to better manage their symptoms and to improve their quality of life. By providing timely and relevant information, virtual assistants can empower patients to take an active role in their care and to make medication informed decisions about their treatment.[52]

**Remote Patient Monitoring and Telehealth**

AI enables remote monitoring and telehealth services, allowing healthcare providers to track patient progress and intervene when necessary. Remote monitoring reduces the need for frequent in-person visits, improving access to care and reducing the burden on healthcare systems.[53] A telehealth platform integrating AI can analyze data from wearable sensors and mobile health applications to monitor PD symptoms remotely. Healthcare providers can review this data in real-time, adjust treatment plans, and provide timely interventions, improving patient outcomes and reducing hospitalizations. Telehealth services can also provide patients with access to specialized care and support, regardless of their location.[54] By leveraging AI and telehealth, healthcare providers can offer more comprehensive and continuous care to PD patients, improving outcomes and reducing the burden on healthcare systems.[55]

**Support for caregivers**

AI tools can assist caregivers by providing insights into patient behavior, predicting care needs, and offering support resources.[56] Caregivers often face significant physical and emotional challenges, and AI can help alleviate some of these burdens. An AI system can analyze data from wearable devices to detect changes in patient behavior that may indicate a need for additional support.[57] Caregivers can receive alerts and recommendations, allowing them to respond promptly to changes in the patient's condition. AI tools can also provide caregivers with information and resources to help them manage their caregiving responsibilities.[58] By offering personalized recommendations and support, AI can help caregivers to better understand and manage the needs of PD patients, improving their quality of life and reducing the burden on caregivers.[59]

## 6. Challenges and Ethical Considerations

**Data Privacy and Security**

Handling sensitive patient data requires stringent data privacy and security measures. AI systems must comply with legal and regulatory frameworks to protect patient information. Ensuring data privacy is crucial for maintaining patient trust and safeguarding against potential breaches.[60] AI models must be designed to anonymize patient data, ensuring that personal information is not exposed. Robust encryption techniques and secure data storage protocols are essential to prevent unauthorized access to patient data.[61] Compliance with data privacy regulations, such as the General Data Protection Regulation (GDPR) in Europe and the Health Insurance Portability and Accountability Act (HIPAA) in the United States, is critical for ensuring the privacy and security of patient data. By implementing robust data privacy and security measures, AI systems can protect patient information and maintain patient trust.[62]

**Ethical Use of AI in Healthcare**

The use of AI in healthcare raises ethical concerns, including the potential for bias in AI algorithms, the need for informed consent, and the transparency of AI decision-making processes. Ensuring that AI models are fair, transparent, and accountable is essential for ethical AI deployment in healthcare.[63] Bias in AI algorithms can arise from unrepresentative training data, leading to disparities in diagnosis and treatment. For instance, if an AI model is trained primarily on data from a specific demographic group, it may not perform as well for patients from other groups. Addressing bias requires careful selection and validation of training data, as well as ongoing monitoring and evaluation of AI models.[64] Informed consent is another critical ethical consideration. Patients must be fully informed about the use of AI in their care, including the potential benefits and risks. Transparent communication about how AI models make decisions and how patient data is used is essential for maintaining trust and ensuring ethical use of AI in healthcare.[65]

**Accessibility and Cost**

Ensuring that AI technologies are accessible and affordable for all patients is crucial to prevent health disparities. Efforts should be made to integrate AI solutions into existing healthcare systems without significant cost barriers.[45] Additionally, addressing the digital divide and ensuring that patients have access to the necessary technology is essential for equitable AI deployment.[66] For instance, telehealth platforms and wearable devices used for remote monitoring should be designed to be user-friendly and affordable. Providing training and support for patients and caregivers can help bridge the digital divide and ensure that AI technologies are accessible to all.[67] Addressing cost barriers and ensuring equitable access to AI technologies can help to prevent health disparities and to ensure that all patients can benefit from the advancements in AI. By making AI technologies accessible and affordable, healthcare providers can improve patient outcomes and reduce the burden on healthcare systems.[68]

## 7. Future directions

**Emerging Technologies and Trends**

Emerging AI technologies, such as federated learning and explainable AI, hold promise for addressing current limitations and enhancing AI applications in PD. Federated learning allows AI models to be trained on decentralized data, preserving privacy while improving model performance. Explainable AI aims to make AI models more transparent and interpretable, enhancing trust and accountability. Federated learning can enable collaboration between multiple healthcare institutions, allowing AI models to be trained on diverse datasets without compromising patient privacy. Explainable AI can provide insights into how AI models make decisions, helping healthcare providers understand and trust AI recommendations.

Other emerging trends include the integration of AI with multi-omics data, which combines genomics, proteomics, and metabolomics data to provide a more comprehensive understanding of PD. AI models can analyze these complex datasets to identify novel biomarkers and therapeutic targets, paving the way for precision medicine in PD.

**Potential Advancements in AI for PD**

Continued research and development in AI can lead to more accurate diagnostic tools, improved monitoring systems, and innovative treatment approaches for PD. Advancements in AI algorithms, data collection techniques, and computational power will drive progress in this field.

For example, integrating AI with multi-omics data, including genomics, proteomics, and metabolomics, can provide a more comprehensive understanding of PD pathophysiology. AI models can analyze these complex datasets to identify novel biomarkers and therapeutic targets, paving the way for precision medicine in PD.

Advancements in AI can also lead to the development of new treatment approaches, such as personalized neuromodulation techniques and AI-driven drug discovery. By leveraging AI, researchers can identify new therapeutic targets and develop more effective treatments for PD, improving patient outcomes and quality of life.

**Collaboration Between AI Experts and Healthcare Professionals**

Collaboration between AI researchers, healthcare providers, and patients is essential for developing AI solutions that are clinically relevant, user-friendly, and effective. Interdisciplinary research and partnerships can drive innovation and ensure that AI technologies are aligned with clinical needs and patient preferences. Involving healthcare providers in the development and validation of AI models can ensure that these tools are practical and effective in clinical settings. Engaging patients and caregivers in the design and implementation of AI solutions can enhance usability and acceptance.

Collaborative efforts can also help to address the ethical and social implications of AI in healthcare, ensuring that AI technologies are deployed in a manner that is fair, transparent, and accountable. By working together, AI researchers, healthcare providers, and patients can drive progress in the field and improve patient outcomes.

## 8. CONCLUSION

AI has the potential to transform the diagnosis, monitoring, treatment, and management of Parkinson's Disease. While there are challenges and ethical considerations to address, the benefits of integrating AI into PD care are significant. Continued advancements in AI technology, combined with collaborative efforts, will pave the way for improved patient outcomes and a better understanding of PD. This review highlights the multifaceted role of AI in PD, emphasizing the importance of ethical and inclusive AI deployment in healthcare. By harnessing the power of AI, we can enhance our ability to diagnose PD early, monitor disease progression more accurately, personalize treatment plans, and provide better support for patients and caregivers. As we move forward, it is crucial to address the challenges and ethical considerations associated with AI in healthcare, ensuring that these technologies benefit all patients and contribute to a more effective and equitable healthcare system.

Through continued research and collaboration, AI can unlock new possibilities in the fight against Parkinson's Disease, improving patient outcomes and quality of life. This review provides a comprehensive overview of the current state and future prospects of AI in PD, offering valuable insights for researchers, healthcare providers, and policymakers.

## REFERENCE


1. Bérard, M.; Sheta, R.; Malvaut, S.; Rodriguez-Aller, R.; Teixeira, M.; Idi, W.; Turmel, R.; Alpaugh, M.; Dubois, M.; Dahmene, M.; et al. A Light-Inducible Protein Clustering System for in Vivo Analysis of α-Synuclein Aggregation in ParkinsonAU Disease: PleasenotethatParkinsonsdiseasehasbeen. *PLoS Biol*, 2022; *20*. doi:10.1371/journal.pbio.3001578.
2. Armstrong, M.J.; Okun, M.S. Diagnosis and Treatment of Parkinson Disease: A Review. *JAMA - J. Am. Med. Assoc*, 2020; *323*: 548–560. doi:10.1001/jama.2019.22360.
3. Tan, E.K.; Chao, Y.X.; West, A.; Chan, L.L.; Poewe, W.; Jankovic, J. Parkinson Disease and the Immune System — Associations, Mechanisms and Therapeutics. *Nat. Rev. Neurol*, 2020; *16*: 303–318. doi:10.1038/s41582-020-0344-4.
4. Willis, A.W.; Roberts, E.; Beck, J.C.; Fiske, B.; Ross, W.; Savica, R.; Van Den Eeden, S.K.; Tanner, C.M.; Marras, C.; Alcalay, R.; et al. Incidence of Parkinson Disease in North America. *npj Park. Dis*, 2022; *8*. doi:10.1038/s41531-022-00410-y.
5. Balestrino, R.; Schapira, A.H.V. Parkinson Disease. *Eur. J. Neurol*, 2020; *27*: 27–42. doi:10.1111/ene.14108.
6. Figueredo, M.B.; Monteiro, R.L.S.; Silva, A. do N.; ... An Approach for Parkinson’s Disease Detection Based on Artificial Inteligence Techniques, 2024. doi:10.21203/rs.3.rs-4468316/v1.
7. Belowska-Bień, K.; Bień, B. Application of Artificial Intelligence and Machine Learning Techniques in Supporting the Diagnosis and Treatment of Neurological Diseases. *Aktual. Neurol*, 2021; *21*: 163–172. doi:10.15557/an.2021.0021.
8. Gantini, T.; Langi, A.Z.R. Artificial Intelligence for Healty Aging : A Literature Review. *Int. Conf. ICT Smart Soc. ICISS 2023 – Proceeding*, 2023; 10. doi:10.1109/ICISS59129.2023.10291625.
9. Donnelly, J.; Dunne, P.J.; Laiti, J.; Loughnane, C.; O’Donovan, R. Digital Positive Health Platforms, Supported By Artificial Intelligence, Measured Using Wearable Devices. *Routledge Int. Handb. Posit. Heal. Sci. Posit. Psychol. Lifestyle Med. Res. Theory Pract*, 2023; 266–281. doi:10.4324/9781003378426-20.
10. Pires, I.M.; Marques, G.; Garcia, N.M.; Pombo, N.; Flórez-Revuelta, F.; Zdravevski, E.; Spinsante, S. A Review on the Artificial Intelligence Algorithms for the Recognition of Activities of Daily Living Using Sensors in Mobile Devices. *Adv. Intell. Syst. Comput*, 2020; *1132*: 685–713. doi:10.1007/978-3-030-40305-8_33.
11. Donnelly, J.; Dunne, P.J.; Laiti, J.; Loughnane, C.; O’Donovan, R. Digital Positive Health Platforms, Supported By Artificial Intelligence, Measured Using Wearable Devices. *Routledge Int. Handb. Posit. Heal. Sci. Posit. Psychol. Lifestyle Med. Res. Theory Pract*, 2023; 266–281. doi:10.4324/9781003378426-20.
12. Li, T.; Le, W. Biomarkers for Parkinson’s Disease: How Good Are They? *Neurosci. Bull*, 2020; *36*: 183–194, doi:10.1007/s12264-019-00433-1.
13. Tracy, J.M.; Özkanca, Y.; Atkins, D.C.; Hosseini Ghomi, R. Investigating Voice as a Biomarker: Deep Phenotyping Methods for Early Detection of Parkinson’s Disease. *J. Biomed. Inform*, 2020; *104*. doi:10.1016/j.jbi.2019.103362.
14. Nancy Noella, R.S.; Priyadarshini, J. Machine Learning Algorithms for the Diagnosis of Alzheimer and Parkinson Disease. *J. Med. Eng. Technol*, 2023; *47*; 35–43. doi:10.1080/03091902.2022.2097326.
15. Md Abu Sayed; Tayaba, M.; Islam, M.T.; Md Eyasin Ul Islam Pavel; Md Tuhin Mia; Eftekhar Hossain Ayon; Nur Nob; Bishnu Padh Ghosh Parkinson’s Disease Detection through Vocal Biomarkers and Advanced Machine Learning Algorithms. *J. Comput. Sci. Technol. Stud*, 2023; *5*: 142–149. doi:10.32996/jcsts.2023.5.4.14.
16. Rana, A.; Dumka, A.; Singh, R.; Panda, M.K.; Priyadarshi, N.; Twala, B. Imperative Role of Machine Learning Algorithm for Detection of Parkinson’s Disease: Review, Challenges and Recommendations. *Diagnostics*, 2022; *12*. doi:10.3390/diagnostics12082003.
17. Sigcha, L.; Borzì, L.; Amato, F.; Rechichi, I.; Ramos-Romero, C.; Cárdenas, A.; Gascó, L.; Olmo, G. Deep Learning and Wearable Sensors for the

Diagnosis and Monitoring of Parkinson's Disease: A Systematic Review. *Expert Syst. Appl*, 2023; *229*: 120541. doi:10.1016/j.eswa.2023.120541.
18. Solana-Lavalle, G.; Rosas-Romero, R. Classification of PPMI MRI Scans with Voxel-Based Morphometry and Machine Learning to Assist in the Diagnosis of Parkinson's Disease. *Comput. Methods Programs Biomed*, 2021; *198*: 105793. doi:10.1016/j.cmpb.2020.105793.
19. Patwekar, M.; Patwekar, F.; Sanaullah, S.; Shaikh, D.; Almas, U.; Sharma, R. Harnessing Artificial Intelligence for Enhanced Parkinson's Disease Management: Pathways, Treatment, and Prospects. *Trends Immunother*, 2023; *7*. doi:10.24294/ti.v7.i2.2395.
20. Rana, A.; Dumka, A.; Singh, R.; Panda, M.K.; Priyadarshi, N. A Computerized Analysis with Machine Learning Techniques for the Diagnosis of Parkinson's Disease: Past Studies and Future Perspectives. *Diagnostics*, 2022; *12*. doi:10.3390/diagnostics12112708.
21. Suppa, A.; Costantini, G.; Asci, F.; Di Leo, P.; Al-Wardat, M.S.; Di Lazzaro, G.; Scalise, S.; Pisani, A.; Saggio, G. Voice in Parkinson's Disease: A Machine Learning Study. *Front. Neurol*, 2022; *13*. doi:10.3389/fneur.2022.831428.
22. Karaman, O.; Çakın, H.; Alhudhaif, A.; Polat, K. Robust Automated Parkinson Disease Detection Based on Voice Signals with Transfer Learning. *Expert Syst. Appl*, 2021; *178*. doi:10.1016/j.eswa.2021.115013.
23. Júnior, E.P.; Delmiro, I.L.D.; Magaia, N.; Maia, F.M.; Hassan, M.M.; Albuquerque, V.H.C.; Fortino, G. Intelligent Sensory Pen for Aiding in the Diagnosis of Parkinson's Disease from Dynamic Handwriting Analysis. *Sensors (Switzerland)*, 2020; *20*: 1–21. doi:10.3390/s20205840.
24. Costantini, G.; Cesarini, V.; Di Leo, P.; Amato, F.; Suppa, A.; Asci, F.; Pisani, A.; Calculli, A.; Saggio, G. Artificial Intelligence-Based Voice Assessment of Patients with Parkinson's Disease Off and On Treatment: Machine vs. Deep-Learning Comparison. *Sensors*, 2023; *23*. doi:10.3390/s23042293.
25. Mei, J.; Desrosiers, C.; Frasnelli, J. Machine Learning for the Diagnosis of Parkinson's Disease: A Review of Literature. *Front. Aging Neurosci*, 2021; *13*. doi:10.3389/fnagi.2021.633752.
26. Wang, W.; Lee, J.; Harrou, F.; Sun, Y. Early Detection of Parkinson's Disease Using Deep Learning and Machine Learning. *IEEE Access*, 2020; *8*: 147635–147646, doi:10.1109/ACCESS.2020.3016062.
27. Sica, M.; Tedesco, S.; Crowe, C.; Kenny, L.; Moore, K.; Timmons, S.; Barton, J.; O'Flynn, B.; Komaris, D.S. Continuous Home Monitoring of Parkinson's Disease Using Inertial Sensors: A Systematic Review. *PLoS One*, 2021; *16*: e0246528. doi:10.1371/journal.pone.0246528.
28. Talitckii, A.; Kovalenko, E.; Shcherbak, A.; Anikina, A.; Bril, E.; Zimniakova, O.; Semenov, M.; Dylov, D. V.; Somov, A. Comparative Study of Wearable Sensors, Video, and Handwriting to Detect Parkinson's Disease. *IEEE Trans. Instrum. Meas*, 2022; *71*. doi:10.1109/TIM.2022.3176898.
29. Goel, N.; Khanna, A.; Gupta, D.; Gupta, N. Detection of Parkinson's Disease Using Machine Learning Techniques for Voice and Handwriting Features. *Adv. Intell. Syst. Comput*, 2020; *1087*: 631–643. doi:10.1007/978-981-15-1286-5_56.
30. Roy, S. AI Integration for Parkinson ' s Disease Management : A New Era of Therapy and Diagnosis. *Mlha, 2024;* 2024.
31. Raundale, P.; Thosar, C.; Rane, S. Prediction of Parkinson's Disease and Severity of the Disease Using Machine Learning and Deep Learning Algorithm. *2021 2nd Int. Conf. Emerg. Technol. INCET*, *2021*; 2021. doi:10.1109/INCET51464.2021.9456292.
32. Richardson, J.P.; Smith, C.; Curtis, S.; Watson, S.; Zhu, X.; Barry, B.; Sharp, R.R. Patient Apprehensions about the Use of Artificial Intelligence in Healthcare. *npj Digit. Med*, 2021; *4*. doi:10.1038/s41746-021-00509-1.
33. Zhang, L.; Zhang, L. Artificial Intelligence for Remote Sensing Data Analysis: A Review of Challenges and Opportunities. *IEEE Geosci. Remote Sens. Mag*, 2022; *10*: 270–294, doi:10.1109/MGRS.2022.3145854.
34. Luan, H.; Geczy, P.; Lai, H.; Gobert, J.; Yang, S.J.H.; Ogata, H.; Baltes, J.; Guerra, R.; Li, P.; Tsai, C.C. Challenges and Future Directions of Big Data and Artificial Intelligence in Education. *Front. Psychol*, 2020; *11*. doi:10.3389/fpsyg.2020.580820.
35. Sahu, M.; Gupta, R.; Ambasta, R.K.; Kumar, P. Artificial Intelligence and Machine Learning in Precision Medicine: A Paradigm Shift in Big Data Analysis. *Prog. Mol. Biol. Transl. Sci*, 2022; *190*: 57–100. doi:10.1016/bs.pmbts.2022.03.002.
36. Saxena, M.; Ahuja, S. Comparative Survey of Machine Learning Techniques for Prediction of Parkinson's Disease. *Indo - Taiwan 2nd Int. Conf. Comput. Anal. Networks, Indo-Taiwan ICAN, 2020;* 2020: 248–253. doi:10.1109/Indo-TaiwanICAN48429.2020.9181368.
37. Sivaparthipan, C.B.; Muthu, B.A.; Manogaran, G.; Maram, B.; Sundarasekar, R.; Krishnamoorthy, S.; Hsu, C.H.; Chandran, K. Innovative and Efficient Method of Robotics for Helping the Parkinson's Disease Patient Using IoT in Big Data Analytics. *Trans. Emerg. Telecommun. Technol*, 2020; *31*. doi:10.1002/ett.3838.
38. Gupta, R.; Kumari, S.; Senapati, A.; Ambasta, R.K.; Kumar, P. New Era of Artificial Intelligence and Machine Learning-Based Detection, Diagnosis, and Therapeutics in Parkinson's Disease. *Ageing Res. Rev*, 2023; *90*. doi:10.1016/j.arr.2023.102013.
39. Ahmed, Z.; Mohamed, K.; Zeeshan, S.; Dong, X.Q. Artificial Intelligence with Multi-Functional Machine Learning Platform Development for Better Healthcare and Precision Medicine. *Database*, 2020;

*2020*. doi:10.1093/database/baaa010.
40. Sollini, M.; Bartoli, F.; Marciano, A.; Zanca, R.; Slart, R.H.J.A.; Erba, P.A. Artificial Intelligence and Hybrid Imaging: The Best Match for Personalized Medicine in Oncology. *Eur. J. Hybrid Imaging*, 2020; *4*. doi:10.1186/s41824-020-00094-8.
41. Bindra, S.; Jain, R. Artificial Intelligence in Medical Science: A Review. *Ir. J. Med. Sci*, 2024; *193*: 1419–1429, doi:10.1007/s11845-023-03570-9.
42. Tripathi, A.; Misra, K.; Dhanuka, R.; Singh, J.P. Artificial Intelligence in Accelerating Drug Discovery and Development. *Recent Pat. Biotechnol*, 2023; *17*: 9–23. doi:10.2174/1872208316666220802151129.
43. Gupta, R.; Srivastava, D.; Sahu, M.; Tiwari, S.; Ambasta, R.K.; Kumar, P. Artificial Intelligence to Deep Learning: Machine Intelligence Approach for Drug Discovery. *Mol. Divers*, 2021; *25*: 1315–1360, doi:10.1007/s11030-021-10217-3.
44. T.R., M.; V., V.K.; Bhardwaj, R.; Khan, S.B.; Alkhaldi, N.; Victor, N.; Verma, A. An Artificial Intelligence-Based Decision Support System for Early and Accurate Diagnosis of Parkinson's Disease. *Decis. Anal. J*, 2024; *10*: doi:10.1016/j.dajour.2023.100381.
45. Salam, A.; Abhinesh, N. Revolutionizing Dermatology: The Role of Artificial Intelligence in Clinical Practice. *IP Indian J. Clin. Exp. Dermatology*, 2024; *10*: 107–112. doi:10.18231/j.ijced.2024.021.
46. Wong, J.K.; Mayberg, H.S.; Wang, D.D.; Richardson, R.M.; Halpern, C.H.; Krinke, L.; Arlotti, M.; Rossi, L.; Priori, A.; Marceglia, S.; et al. Proceedings of the 10th Annual Deep Brain Stimulation Think Tank: Advances in Cutting Edge Technologies, Artificial Intelligence, Neuromodulation, Neuroethics, Interventional Psychiatry, and Women in Neuromodulation. *Front. Hum. Neurosci*, 2023; *16*. doi:10.3389/fnhum.2022.1084782.
47. Connolly, M.J.; Cole, E.R.; Isbaine, F.; De Hemptinne, C.; Starr, P.A.; Willie, J.T.; Gross, R.E.; Miocinovic, S. Multi-Objective Data-Driven Optimization for Improving Deep Brain Stimulation in Parkinson's Disease. *J. Neural Eng*, 2021; *18*. doi:10.1088/1741-2552/abf8ca.
48. Oliveira, A.M.; Coelho, L.; Carvalho, E.; Ferreira-Pinto, M.J.; Vaz, R.; Aguiar, P. Machine Learning for Adaptive Deep Brain Stimulation in Parkinson's Disease: Closing the Loop. *J. Neurol*, 2023; *270*: 5313–5326, doi:10.1007/s00415-023-11873-1.
49. Sarikhani, P.; Ferleger, B.; Mitchell, K.; Ostrem, J.; Herron, J.; Mahmoudi, B.; Miocinovic, S. Automated Deep Brain Stimulation Programming with Safety Constraints for Tremor Suppression in Patients with Parkinson's Disease and Essential Tremor. *J. Neural Eng*, 2022; *19*. doi:10.1088/1741-2552/ac86a2.
50. Iqbal, J.; Cortés Jaimes, D.C.; Makineni, P.; Subramani, S.; Hemaida, S.; Thugu, T.R.; Butt, A.N.; Sikto, J.T.; Kaur, P.; Lak, M.A.; et al. Reimagining Healthcare: Unleashing the Power of Artificial Intelligence in Medicine. *Cureus*, 2023. doi:10.7759/cureus.44658.
51. Babar Malik, J. Artificial Intelligence Enabled Healthcare: Opportunities and Challenges for Patients with Dementia, 2023.
52. Rahman, W.; Abdelkader, A.; Lee, S.; Yang, P.; Islam, M.S.; Adnan, T.; Hasan, M.; Wagner, E.; Park, S.; Dorsey, E.R.; et al. A User-Centered Framework to Empower People with Parkinson's Disease. *Proc. ACM Interactive, Mobile, Wearable Ubiquitous Technol*, 2024; *7*: 175. doi:10.1145/3631430.
53. Motolese, F.; Magliozzi, A.; Puttini, F.; Rossi, M.; Capone, F.; Karlinski, K.; Stark-Inbar, A.; Yekutieli, Z.; Di Lazzaro, V.; Marano, M. Parkinson's Disease Remote Patient Monitoring During the COVID-19 Lockdown. *Front. Neurol*, 2020; *11*. doi:10.3389/fneur.2020.567413.
54. Sabatelli, A. Telemonitoring and Telerehabilitation in Parkinson's Disease: An Innovative Approach Using Wearable Devices, 2024.
55. Perju‑dumbrava, L.; Barsan, M.; Leucuta, D.; Popa, L.C.; Pop, C.; Tohanean, N.; Popa, S.L. Artificial Intelligence Applications and Robotic Systems in Parkinson's Disease (Review). *Exp. Ther. Med*, 2021; *23*. doi:10.3892/etm.2021.11076.
56. Godoy Junior, C.A.; Miele, F.; Mäkitie, L.; Fiorenzato, E.; Koivu, M.; Bakker, L.J.; Groot, C.U. de; Redekop, W.K.; van Deen, W.K. Attitudes Toward the Adoption of Remote Patient Monitoring and Artificial Intelligence in Parkinson's Disease Management: Perspectives of Patients and Neurologists. *Patient*, 2024; *17*: 275–285. doi:10.1007/s40271-023-00669-0.
57. Luis-Martínez, R.; Monje, M.H.G.; Antonini, A.; Sánchez-Ferro, Á.; Mestre, T.A. Technology-Enabled Care: Integrating Multidisciplinary Care in Parkinson's Disease Through Digital Technology. *Front. Neurol*, 2020; *11*. doi:10.3389/fneur.2020.575975.
58. Ho, A.; Bavli, I.; Mahal, R.; McKeown, M.J. Multi-Level Ethical Considerations of Artificial Intelligence Health Monitoring for People Living with Parkinson's Disease. *AJOB Empir. Bioet*, 2023, doi:10.1080/23294515.2023.2274582.
59. Wang, L.; Smriti, D.; Yuan, H.; Huh-Yoo, J. Artificial Intelligence Systems for Supporting Informal Caregivers of People Living with Alzheimer's Disease or Related Dementias: A Systematic Review. *Conf. Hum. Factors Comput. Syst. – Proc*, 2024. doi:10.1145/3613905.3650846.
60. Gerke, S.; Minssen, T.; Cohen, G. Ethical and Legal Challenges of Artificial Intelligence-Driven Healthcare. *Artif. Intell. Healthc*, 2020; 295–336. doi:10.1016/B978-0-12-818438-7.00012-5.
61. Sujith, A.V.L.N.; Sajja, G.S.; Mahalakshmi, V.; Nuhmani, S.; Prasanalakshmi, B. Systematic Review of Smart Health Monitoring Using Deep Learning

and Artificial Intelligence. *Neurosci. Informatics*, 2022; *2*: 100028, doi:10.1016/j.neuri.2021.100028.
62. khan, B.; Fatima, H.; Qureshi, A.; Kumar, S.; Hanan, A.; Hussain, J.; Abdullah, S. Drawbacks of Artificial Intelligence and Their Potential Solutions in the Healthcare Sector. *Biomed. Mater. Devices*, 2023; *1*: 731–738, doi:10.1007/s44174-023-00063-2.
63. Solanki, P.; Grundy, J.; Hussain, W. Operationalising Ethics in Artificial Intelligence for Healthcare: A Framework for AI Developers. *AI Ethics*, 2023; *3*: 223–240, doi:10.1007/s43681-022-00195-z.
64. Naik, N.; Hameed, B.M.Z.; Shetty, D.K.; Swain, D.; Shah, M.; Paul, R.; Aggarwal, K.; Brahim, S.; Patil, V.; Smriti, K.; et al. Legal and Ethical Consideration in Artificial Intelligence in Healthcare: Who Takes Responsibility? *Front. Surg*, 2022; *9*. doi:10.3389/fsurg.2022.862322.
65. Solanki, P.; Grundy, J.; Hussain, W. Operationalising Ethics in Artificial Intelligence for Healthcare: A Framework for AI Developers. *AI Ethics*, 2023; *3*; 223–240. doi:10.1007/s43681-022-00195-z.
66. Godoy Junior, C.A.; Miele, F.; Mäkitie, L.; Fiorenzato, E.; Koivu, M.; Bakker, L.J.; Groot, C.U. de; Redekop, W.K.; van Deen, W.K. Attitudes Toward the Adoption of Remote Patient Monitoring and Artificial Intelligence in Parkinson's Disease Management: Perspectives of Patients and Neurologists. *Patient*, 2024; *17*: 275–285, doi:10.1007/s40271-023-00669-0.
67. Rogers, W.A.; Draper, H.; Carter, S.M. Evaluation of Artificial Intelligence Clinical Applications: Detailed Case Analyses Show Value of Healthcare Ethics Approach in Identifying Patient Care Issues. *Bioethics*, 2021; *35*: 623–633. doi:10.1111/bioe.12885.
68. Grzybowski, A.; Jin, K.; Wu, H. Challenges of Artificial Intelligence in Medicine and Dermatology. *Clin. Dermatol*, 2024; *42*: 210–215, doi:10.1016/j.clindermatol.2023.12.013